H
Hutchmed(HMDCF)
China - Hong Kong
BiotechnologyFocus: Oral drugs
Error: Unreachable/Blocked
OncologyImmunologyHematologyNephrologyGastroenterology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Surufatinib
Neuroendocrine TumorsClinical Trials (1)
NCT04814732Expanded Access Program of Surufatinib
N/AElunate®
Patient SafetyClinical Trials (1)
NCT04005066A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients
N/AHMPL-523
Rheumatoid Arthritis (RA)Clinical Trials (1)
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
Phase 1Sulfatinib
Neuroendocrine TumorsClinical Trials (1)
NCT02267967Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Phase 1Volitinib
Non-Small Cell Lung CancerClinical Trials (1)
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
Phase 1HMPL-689
LymphomasClinical Trials (1)
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Phase 1Sulfatinib
TumorClinical Trials (1)
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
Phase 1Surufatinib
Hepatic ImpairmentClinical Trials (1)
NCT04755075Surufatinib Hepatic Impairment Study
Phase 1HMPL-415S1
Advanced Malignant Solid TumorsClinical Trials (1)
NCT05886374A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
Phase 1HMPL-760
B-Cell Non-Hodgkin's LymphomaClinical Trials (1)
NCT05190068HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1HMPL-453
Solid TumorClinical Trials (1)
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Phase 1Fruquintinib
TumorClinical Trials (1)
NCT01645215Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
Phase 1HMPL-523
Healthy SubjectClinical Trials (1)
NCT05318820A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
Phase 1HMPL-523 Acetate Tablets
HealthyClinical Trials (1)
NCT07331194Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans
Phase 1HMPL-689
LymphomaClinical Trials (1)
NCT03786926Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Phase 1HMPL-653
Advanced Malignant Solid TumorsClinical Trials (1)
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
Phase 1HMPL-011 tablets
Inflammatory Bowel DiseasesClinical Trials (1)
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
Phase 1Phase 1
Clinical Trials (1)
NCT04764474A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Phase 1Sulfatinib T capsule
Relative BioavailabilityClinical Trials (1)
NCT03483259To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
Phase 1Phase 1
Clinical Trials (1)
NCT07025018Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Phase 1HMPL-523
Hematologic MalignanciesClinical Trials (1)
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Phase 1HMPL-523
Immune Thrombocytopenia (ITP)Clinical Trials (1)
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
Phase 1Volitinib
TumorClinical Trials (1)
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
Phase 1Fruquintinib
Drug Drug InteractionClinical Trials (1)
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
Phase 1HMPL-523
Mature B-cell NeoplasmsClinical Trials (1)
NCT02857998A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Phase 1Itraconazole 200 mg
Relapsed or Refractory LymphomaClinical Trials (1)
NCT05602597HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Phase 1Phase 1
Clinical Trials (1)
NCT04762602A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Phase 1HMPL-453
Intrahepatic CholangiocarcinomaClinical Trials (1)
NCT05930119HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
Phase 1HMPL-A83 injection
Advanced TumorsClinical Trials (1)
NCT05429008A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
Phase 1100 µCi [14C] HMPL-306
Mass Balance StudyClinical Trials (1)
NCT06671873Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
Phase 1HMPL-523
Relapsed or Refractory LymphomaClinical Trials (1)
NCT05720767HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Phase 1HMPL-506
Hematological MalignanciesClinical Trials (1)
NCT06387082A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
Phase 1Theliatinib
CancerClinical Trials (1)
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
Phase 1[14C]Sulfatinib
HealthyClinical Trials (1)
NCT03627520A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
Phase 1HMPL-523
Non Hodgkin LymphomaClinical Trials (1)
NCT03779113An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Phase 1HMPL-523
Acute Myeloid LeukemiaClinical Trials (1)
NCT03483948Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
Phase 1Volitinib
Food EffectClinical Trials (1)
NCT02017236A Food Effect Phase I Study of the Volitinib in Healthy Subjects
Phase 1surufatinib
HealthyClinical Trials (1)
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
Phase 1Fruquintinib
Metastatic Colorectal CancerClinical Trials (1)
NCT05368805Fruquintinib DDI Study With P-gp and BCRP Substrates
Phase 1Part A
HealthyClinical Trials (1)
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
Phase 1fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole
Drug InteractionClinical Trials (1)
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
Phase 1HMPL-760
CLL/SLLClinical Trials (1)
NCT05176691HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Phase 1HMPL-689
Healthy VolunteersClinical Trials (1)
NCT02631642A Study of HMPL-689 in Healthy Volunteers
Phase 1Fruquintinib
Hepatic ImpairmentClinical Trials (1)
NCT05216367Fruquintinib Hepatic Impairment Study
Phase 1Epitinib
Solid TumorClinical Trials (1)
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05781906Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
Phase 1Sulfatinib
HealthyClinical Trials (1)
NCT02320409A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
Phase 1Surufatinib
Renal ImpairmentClinical Trials (1)
NCT04755088Surufatinib Renal Impairment Study
Phase 1fruquintinib
HealthyClinical Trials (1)
NCT02689752A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib
Phase 1Savolitinib Test Preparation
BioequivalenceClinical Trials (1)
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
Phase 1Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 112 clinical trials
Top TAs: Oncology
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles